IRIS
CIVES, MAURO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.486
AS - Asia 2.163
EU - Europa 1.437
SA - Sud America 665
AF - Africa 100
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.859
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.393
SG - Singapore 852
BR - Brasile 520
CN - Cina 492
IT - Italia 322
HK - Hong Kong 265
SE - Svezia 221
RU - Federazione Russa 197
VN - Vietnam 194
FI - Finlandia 140
FR - Francia 135
DE - Germania 121
GB - Regno Unito 108
IN - India 73
AR - Argentina 56
ID - Indonesia 49
BD - Bangladesh 46
CA - Canada 43
IQ - Iraq 38
JP - Giappone 29
ZA - Sudafrica 29
MX - Messico 27
NL - Olanda 27
TR - Turchia 26
CI - Costa d'Avorio 25
AT - Austria 23
CO - Colombia 22
PL - Polonia 22
UA - Ucraina 22
BE - Belgio 21
PK - Pakistan 18
ES - Italia 14
VE - Venezuela 14
EC - Ecuador 13
IE - Irlanda 13
LT - Lituania 13
MA - Marocco 12
PH - Filippine 12
PY - Paraguay 12
SA - Arabia Saudita 12
CL - Cile 11
BO - Bolivia 7
KE - Kenya 7
UZ - Uzbekistan 7
JO - Giordania 6
MY - Malesia 6
RS - Serbia 6
TN - Tunisia 6
UY - Uruguay 6
AL - Albania 5
AZ - Azerbaigian 5
CR - Costa Rica 5
EG - Egitto 5
ET - Etiopia 5
MK - Macedonia 5
OM - Oman 5
HU - Ungheria 4
PE - Perù 4
TH - Thailandia 4
AU - Australia 3
BB - Barbados 3
DO - Repubblica Dominicana 3
HN - Honduras 3
KZ - Kazakistan 3
NP - Nepal 3
RO - Romania 3
AE - Emirati Arabi Uniti 2
AO - Angola 2
CH - Svizzera 2
DZ - Algeria 2
GR - Grecia 2
HR - Croazia 2
IL - Israele 2
JM - Giamaica 2
LB - Libano 2
MN - Mongolia 2
MT - Malta 2
NZ - Nuova Zelanda 2
TT - Trinidad e Tobago 2
XK - ???statistics.table.value.countryCode.XK??? 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BY - Bielorussia 1
DM - Dominica 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
IR - Iran 1
IS - Islanda 1
JE - Jersey 1
KG - Kirghizistan 1
KR - Corea 1
LV - Lettonia 1
MD - Moldavia 1
MG - Madagascar 1
MM - Myanmar 1
NG - Nigeria 1
NI - Nicaragua 1
PR - Porto Rico 1
Totale 8.849
Salva come PNG Salva come JPEG
Città #
Ashburn 571
Fairfield 502
Singapore 460
Woodbridge 389
Hong Kong 262
Houston 231
Seattle 220
Chandler 210
San Jose 205
Cambridge 203
Beijing 196
Nyköping 186
Wilmington 186
Ann Arbor 123
Helsinki 109
Los Angeles 83
Lauterbourg 78
New York 69
Dallas 65
Lawrence 64
Ho Chi Minh City 63
Jacksonville 61
Roxbury 58
Bari 48
Council Bluffs 47
São Paulo 45
Jakarta 41
Nanjing 39
Des Moines 36
Santa Clara 36
Chicago 33
Buffalo 32
London 32
Boardman 29
Inglewood 28
Munich 28
Abidjan 24
Hanoi 24
Dong Ket 23
Falkenstein 23
Paris 23
Tokyo 23
Rome 22
Redwood City 21
Brooklyn 20
Johannesburg 20
Brussels 19
San Diego 19
Nuremberg 18
Warsaw 18
Brasília 17
Belo Horizonte 15
Chennai 15
Moscow 15
Orem 15
Princeton 15
Curitiba 14
Montreal 14
Turku 14
Dublin 13
Frankfurt am Main 13
Buenos Aires 12
Rio de Janeiro 12
Baghdad 11
Düsseldorf 11
Mexico City 10
Shenyang 10
Stockholm 10
Toronto 10
Vienna 10
Dearborn 9
Elk Grove Village 9
Haiphong 9
Milan 9
Nanchang 9
Naples 9
Phoenix 9
Porto Alegre 9
Can Tho 8
Changsha 8
Columbus 8
Denver 8
Medellín 8
Pune 8
San Francisco 8
Amsterdam 7
Ankara 7
Atlanta 7
Dhaka 7
Guangzhou 7
Ninh Bình 7
Vibo Valentia 7
Bologna 6
Boston 6
Calgary 6
Da Nang 6
Hebei 6
Istanbul 6
Jiaxing 6
Montevideo 6
Totale 5.846
Salva come PNG Salva come JPEG
Nome #
Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors 260
Gastroenteropancreatic Neuroendocrine Tumors 186
Exosomes in melanoma: A role in tumor progression, metastasis and impaired immune system activity 179
Osteotropism of neuroendocrine tumors: Role of the CXCL12/ CXCR4 pathway in promoting EMT in vitro 171
Extracellular Vesicles and Epigenetic Modifications Are Hallmarks of Melanoma Progression 171
Everolimus restrains the paracrine pro-osteoclast activity of breast cancer cells 170
Reviewing the Osteotropism in Neuroendocrine Tumors: The Role of Epithelial-Mesenchymal Transition 169
Bendamustine overcomes resistance to melphalan in myeloma cell lines by inducing cell death through mitotic catastrophe 163
Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. 162
Management of Asymptomatic Sporadic Nonfunctioning Pancreatic Neuroendocrine Neoplasms (ASPEN) ≤2 cm: Study Protocol for a Prospective Observational Study 160
Erdheim-Chester disease: A systematic review. 158
New insights into the molecular pathogenesis of langerhans cell histiocytosis 157
The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications 157
A Delphic consensus assessment: imaging and biomarkers in gastroenteropancreatic neuroendocrine tumor disease management. 156
Parallelism of DOG1 expression with recurrence risk in gastrointestinal stromal tumors bearing KIT or PDGFRA mutations 154
Sirtuins and Cancer: Role in the Epithelial-Mesenchymal Transition 153
The Role of Cytotoxic Chemotherapy in Well-Differentiated Gastroenteropancreatic and Lung Neuroendocrine Tumors. 151
NETs: Organ-related epigenetic derangements and potential clinical applications 146
Development of anti-somatostatin receptors CAR T cells for treatment of neuroendocrine tumors 143
An update on Merkel cell carcinoma 138
An imbalance between Beclin-1 and p62 expression promotes the proliferation of myeloma cells through autophagy regulation. 137
Analysis of the immune landscape of small bowel neuroendocrine tumors 134
Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors 132
Cerebellar ataxia and exercise intolerance in Erdheim-Chester disease 130
Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors 125
Lenalidomide in multiple myeloma: current experimental and clinical data 122
Analysis of Postoperative Recurrence in Stage I-III Midgut Neuroendocrine Tumors 122
The management of refractory carcinoid syndrome: challenges and opportunities ahead 119
SNPs in predicting clinical efficacy and toxicity of chemotherapy: Walking through the quicksand 119
A phase II study of axitinib in advanced neuroendocrine tumors 118
The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors 116
DAXX mutations as potential genomic markers of malignant evolution in small nonfunctioning pancreatic neuroendocrine tumors 112
Role of Bone Targeting Agents in the Prevention of Bone Metastases from Breast Cancer 111
1101MO Development of CAR T-cells for future treatment of NETs 111
Bone Metastases in Neuroendocrine Tumors: Molecular Pathogenesis and Implications in Clinical Practice 107
Local treatment for focal progression in metastatic neuroendocrine tumors 106
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials 106
Effect of vitaxin on hyperactive osteoclastogenesis in multiple myeloma: a preclinical study 104
Radionuclide Therapy for Neuroendocrine Tumors 104
Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems 101
Association of Upfront Peptide Receptor Radionuclide Therapy With Progression-Free Survival Among Patients With Enteropancreatic Neuroendocrine Tumors 100
Cell fusion in myeloma marrow microenvironment: role in tumor progression 99
The psychological impact of COVID-19 pandemic on patients with neuroendocrine tumors: Between resilience and vulnerability 98
Adoptive T-cell immunotherapy in digestive tract malignancies: Current challenges and future perspectives 98
Treatment strategies for metastatic neuroendocrine tumors of the gastrointestinal tract. 97
Local treatment for focal progression in metastatic neuroendocrine tumors 97
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives 96
An update on gastroenteropancreatic neuroendocrine tumors 96
Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours 96
In search of a bone metastasis (BM) gene signature in circulating tumour cells (CTCs) from stage IV breast cancer (BC) patients 96
Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications 94
A Phase II Study of Ibrutinib in Advanced Neuroendocrine Neoplasms 93
Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors 93
Novel Lenalidomide-based combinations for treatment of multiple myeloma 92
Non-Melanoma Skin Cancers: Biological and Clinical Features 92
Assessment of bone turnover markers and DXA parameters to predict bone metastasis progression during zoledronate treatment: a single-center experience 91
Adamantinoma-like Ewing sarcoma of the salivary glands: a case report and systematic literature review 90
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 88
Therapy for locoregional disease: pancreas 86
Higher frequency of isolated PMS2 loss in colorectal tumors in Colombian population: preliminary results 85
Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3rd-line treatment 82
Management of NETs in the Precision Medicine Era 81
Randomised phase II trial of CAPTEM or FOLFIRI as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET/CT imaging and biological markers (SENECA trial): A study protocol 80
Lanreotide dopo octreotide LAR nel pNET in progressione: descrizione di un caso 79
Sensitivity and Specificity of the NETest: A Validation Study 78
Somatostatin Analogs for Pancreatic Neuroendocrine Tumors: Any Benefit When KI-67 is ≥10%? 76
Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML 75
Sequencing Treatments in Patients with Advanced Well-Differentiated Pancreatic Neuroendocrine Tumor (pNET): Results from a Large Multicenter Italian Cohort 69
Extrapulmonary Neuroendocrine Carcinomas: Current Management and Future Perspectives 67
Neuroendocrine tumors 65
EPB41L5 is Associated with the Metastatic Potential of Low-grade Pancreatic Neuroendocrine Tumors 65
Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours 65
An Immunohistochemical Score as Predictor of the Bone Metastasis Risk in Patients with NETs 62
Epidemiology of gastroenteropancreatic neuroendocrine neoplasms: a review and protocol presentation for bridging tumor registry data with the Italian association for neuroendocrine tumors (Itanet) national database 61
Novel immunotherapy strategies for treatment of neuroendocrine neoplasms 60
The future of cellular therapy for the treatment of renal cell carcinoma 58
A challenge in emergency department: a case report of oxaliplatin-induced Kounis syndrome 53
Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet) 48
Radioligand therapy in the therapeutic strategy for patients with gastro-entero-pancreatic neuroendocrine tumors: a consensus statement from the Italian Association for Neuroendocrine Tumors (Itanet), Italian Association of Nuclear Medicine (AIMN), Italian Society of Endocrinology (SIE), Italian Association of Medical Oncology (AIOM) 46
The impact of COVID-19 on the management of neuroendocrine tumors (NETS): An international NET CONNECT survey of NET patients and healthcare professionals treating net patients 44
Is NETTER-2 a practice-changing trial? 43
Management of asymptomatic sporadic non-functioning pancreatic neuroendocrine neoplasms no larger than 2 cm: interim analysis of prospective ASPEN trial 39
Epidemiology and geographic clustering of Erdheim-Chester disease in Italy and France 37
Mixed neuroendocrine non-neuroendocrine tumors: The quest for evidence 36
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 35
In Defense of Neuroendocrine Tumor Trials 34
Peptide receptor radionuclide therapy in G3 gastroenteropancreatic neuroendocrine tumors: a missed opportunity for European patients? 28
Pancreatic neuroendocrine neoplasms (pNENs): Genetic and environmental biomarkers for risk of occurrence and prognosis 27
SPINK2 silencing suppresses leukemic proliferation and restores myeloid commitment via MECOM downregulation in acute myeloid leukaemia 26
Enhancing patient-centered care with AI: a study of responses to neuroendocrine neoplasms queries 25
The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion 24
White paper on best practices for translational research in neuroendocrine neoplasms 23
COVID-19 in patients with neuroendocrine neoplasms: 2-year results of the INTENSIVE study 22
Diagnosis and treatment of paragangliomas and pheochromocytomas: a survey from the Italian Association for Neuroendocrine Tumors 13
Totale 9.243
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.405
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.405
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202154 0 0 0 0 0 0 0 0 0 0 0 54
2021/2022444 42 19 3 10 17 50 14 18 38 37 71 125
2022/2023636 91 111 47 31 37 92 19 87 82 2 17 20
2023/2024313 19 55 14 38 35 63 18 11 6 13 4 37
2024/20251.610 49 27 128 83 57 129 162 129 96 164 207 379
2025/20263.678 557 200 255 472 409 210 380 143 447 379 152 74
Totale 9.243